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THE IMPACT OF CURRENT POLICY AND 
REGULATION ON FUTURE STEM CELL 
HUMAN HEAL TH APPLICATIONS 
MICHAEL J. MALINOWSKI* 
INTRODUCTION 
My approach to bioethics is very much application centered, meaning 
in part that I prioritize reality and ongoing human experiences-the impact 
on lives in motion today-over theory, with appreciation that the two often 
work well together.1 I use theory to assist in problem identification and 
analysis, but I favor a fact-based approach driven by what people are 
actually living through today.2 While doing so, I also try to be thoughtful 
and think longer term and proactively. 
I believe that those of us who invest our professional lives in bioethics 
and health policy have an obligation to be professionally self-aware and 
open. We must figure out what drives our thinking and why, identify where 
we stand on particular issues and why, and then disclose that information 
honestly when we enter debates. Otherwise, meaningful communication 
* 
I. 
2. 
Ernest R. and Iris M. Eldred Professor of Law and Associate Director, Program in 
Law, Science, and Public Health, Paul M. Hebert Law Center, Louisiana State 
University. The presentation for this live symposium on November 19, 2004 was 
derived from another given by the author on October 11, 2004 at National Academies, 
Workshop on Guidelines for Human Embryonic Stem Cell Research (Oct. 11-12, 
2004, Washington, D.C.). The author would like to thank Professor R. Alta Charo for 
interactions in conjunction with the Workshop that contributed to this effort, Professor 
Nanette Elster for her thoughtful suggestion, and Daven Williams for her research 
assistance. 
See Michael J. Malinowski, Law, Policy, and Market Implications of Genetic 
Profiling in Drug Development, Hous. J. HEALTH LAW & PoL'Y 31, 59-61 (2002). 
"One might argue, therefore, that there is a moral imperative in addition to a 
professional obligation to bridge law and policy with meaningful fieldwork .... in both 
life science R&D and health care delivery .... " Id at 61. 
See generally id. 
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and dialogue are unlikely. Even if more often than not we end up agreeing 
that we disagree because our personal determinants on an issue are not 
aligned, we can do so with a baseline of communication and understanding, 
and relay the same to others in the debate. 
Given this approach, today's topic certainly necessitates some 
disclosure by me at the outset. Therefore, I will begin by explaining my 
position on human embryonic stem cell research (hESCR) and my 
underlying rationale for my position. In Part II of this presentation, I will 
address the impact of current federal policy and regulation on hESCR in 
the context of ongoing basic research. In Part III, I will discuss the potential 
impact of existing federal policy and regulations on human health 
applications of hESCR. I will conclude in Part IV by sharing my overriding 
thoughts about the regulatory environment for hESCR in the United States. 
Given the chronic commingling of therapeutic and reproductive cloning 
since the late 1990s, I believe that assurance to quell discomfort with the 
notion of human cloning for reproduction is a prerequisite for significantly 
increasing support for hESCR in the near future. As I will explain, I believe 
that such assurance is possible only through more meaningful regulatory 
oversight and accountability in the field of assisted reproduction (AR) in 
the United States. 
I. OVERALL POSITION ON HESCR 
My position on hESCR is influenced heavily by the state of AR in the 
United States, and I believe that these issues are fundamentally entangled. 
AR has become a burgeoning, multibillion-dollar industry annually in this 
country, and one that is growing exponentially.3 Professor George Annas 
has done a wonderful job- in literature, in presentations, and in the popular 
media, including a PBS documentary entitled Making Babies that I have 
shown often in my classes4-drawing attention to the dearth of U.S. federal 
regulation in the field of AR. 5 Professor Annas has referred to AR in the 
3. See Michael J. Malinowski, Choosing the Genetic Makeup of Children: Our Eugenics 
Past-Present, and Future?, 36 CONN. L. REv. 125, 179-97 (2003) (fully explaining 
the present state of regulation of AR in the U.S., including dependence upon 
voluntary reporting, and the market, social, and scientific factors driving extensive 
expansion of use of AR technologies). Cf PRESIDENT'S COUNCIL ON BIOETHICS, 
REPRODUCTION AND RESPONSIBILITY: THE REGULATION OF NEW BIOTECHNOLOGIES 
54-63 (2004), available at http://www.bioethics.gov/reports/reproductionand 
responsibility/ _pcbe _ final_reproduction_ and _responsibility. pdf [hereinafter 
PRESIDENT ' S COUNCIL, REPRODUCTION AND RESPONSIBILITY]. According to one 
report, AR constituted a $4 billion industry annually as of 2001. See id. at 191. 
4. Frontline: Making Babies (PBS television broadcast, June 1, 1999). 
5. See generally George J. Annas, The ABCs of Global Governance of Embryonic Stem 
Cell Research: Arbitrage, Bioethics and Cloning, 39 NEW ENG. L. REV. 489 (2005). 
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United States as "the wild West"6 of American medicine, and that pretty 
h 
. 7 muc captures 1t. 
The consequential reality is that we know, according to data released 
by the American Society for Reproductive Medicine (ASRM) on May 7, 
2003, that we have more than 400,000 frozen embryos left over from AR 
procedures and derogated to what I will call "cryopreservation purgatory."8 
These numbers are probably very low because they are based on self­
reporting,9 and AR has been burgeoning since 2003. Reality is that these 
embryos are the creation of medical intervention and their continued 
existence is wholly dependent upon the same. As we heard this morning 
from Dr. Suzanne Kadereit, 10 Harvard's Boston Children's Hospital is not 
going to pay to keep the embryos perpetuating forever, and we should not 
anticipate more from its sister institutions. 
For the purposes of argument, let us elevate the existence of these 
frozen embryos to a status much higher than what they actually are. Let us 
equate them with people with life histories who are dependent on medical 
intervention for their continued existence-for example, an eighteen-year­
old who suffered severe brain trauma in an automobile accident or an 
eighty-six-year old with very advanced Alzheimer's. It is basic, well 
See, e.g., Rosario M. Isasi & George J. Annas, Arbitrage, Bioethics, and Cloning: The 
ABCs of Gestating A United Nations Cloning Convention, 35 CASE W. RES. J. INT'L L. 
397 (2003). 
6. See Isasi & Annas, supra note 5, at 397. 
7. See Malinowski, supra note 3, at 180-89. 
8. Id. at 130 n.11 (citing American Society for Reproductive Medicine, Vast Majority of 
Cryopreserved Embryos Slated for Future Family Building, ASRM BULL., May 7, 
2003, available at http://www.asrm.org/Washington/Bulletins/vol5no30.html). 
9. The United States relies heavily upon voluntary reporting by those practicing AR. 
The Centers for Disease Control and Prevention (CDC) has contracted 
implementation of the Fertility Clinic Success Rate and Certification Act of 1992, 
Pub. L. 102-493, 106 Stat. 3146 (1992), to the Society for Assisted Reproductive 
Technology (SART), which is part of the American Society for Reproductive 
Medicine (ASRM). Malinowski, supra note 3, at 182. The CDC compiles submitted 
data and publishes reports. See, e.g., CTRS. FOR DISEASE CONTROL & PREVENTION, 
2000 Assisted Reproductive Technology Report, available at http://www.cdc.gov/ 
reproductivehealth/ARTOO/download.htm (Dec. 20, 2002); CTRS. FOR DISEASE 
CONTROL & PREVENTION, 2001 Assisted Reproductive Technology Success Rates, 
available at http://www.cdc.gov/reproductivehealth/ ARTO 1/download.htm (Dec. 
2003). 
10. Suzanne Kadereit & Pamela J. Hines, An Overview of Stem Cell Research, 39 NEW 
ENG. L. REV. 607 (2005). But see Miller v. Am. Infertility Group, No. 02-L-7394 (Cir. 
Ct. Cook County, Ill., County Dep't Law Div., Feb. 4, 2005) (memorandum opinion 
and order) (on file with author) (holding that a couple whose frozen embryos were 
accidentally destroyed at a fertility clinic has the right to file a wrongful death 
lawsuit). 
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established law and policy in the United States and in many other 
industrialized countries that, when a person is incompetent and wholly 
dependent upon medical intervention for his or her continued existen
.
ce, 
and that person has not expressed wishes to the contrary before becommg 
incompetent, the family or guardian of that person has the right to make 
decisions about withdrawing medical intervention. 1 1  Often, the decision to 
withdraw treatment is accompanied by a decision to donate the person's 
physical existence for use in organ transplantation or research to benefit 
others. 12 
When the life lost is a frozen embryo rather than an incompetent 
person, however, President Bush's policy on stem cell research greatly 
impedes the ability of "family members" to mitigate the loss of life by 
making potentially significant health contributions. Under the Bush policy, 
the option to donate cryopreserved embryos is limited to research with 
private money and removed from academic institutions, which 
understandably makes that option much less appealing to many people.13 
The policy also creates a significant disincentive and, at the least, major 
administrative transaction costs for the thousands of academic institutions 
and researchers who receive some of the many billions of taxpayer dollars 
11. BARRY R. FURROW ET AL., HEALTH LAW: CASES, MATERIALS AND PROBLEMS 1379-
1446 (5th ed. 2004); TIMOTHY STOLTZFUS JOST, READINGS I N  COMPARATIVE HEALTH 
LAW & BIOETHICS 299-326 (Carolina Academic Press 2001) (discussing the right to 
die). 
12. See FURROW ET AL., supra note 11, at 1315-43. Cf UNIF. DETERMINATION OF DEATH 
ACT § 1, 12A U.L.A. 593 (1980). The act has been expanded to encompass "brain 
death" in the definition of death and, generally, to make it easier to donate organs for 
transplantation. FURROW ET AL., supra note 11, at 1321. 
13. Fact Sheet, The White House, Embryonic Stem Cell Research (Aug. 9, 2001), 
available at http://www. whitehouse.gov/news/releases/2001/08/20010809-1.html. On 
August 9, 2001, President Bush declared federally funded research permissible on 
hESCs already extracted from embryos at that time. Id.; see also Address to the 
Nation on Stem Cell Research, 2 PUB. PAPERS 953 (Aug. 9, 2001), available at 
http://www.whitehouse.gov/news/releases/2001108/20010809-2.html. Soon after, 
access to and the quality of these lines were called into question. See, e.g., Sheryl Gay 
Stolberg, Ruling by US. Widens Study of Stem Cells, N.Y. TIMES, Aug. 7, 2002, at 
A l .  Recently, these lines have been declared probably useless for human medicinal 
applications because they were created with mouse feeder cells a reflection of the 
state of science at that time, and many are of poor quality. See Karen Kaplan, Study 
Says All Stem Cell Lines Tainted, L.A. TIMES, Jan. 24, 2005, at Al. This issue also 
was raised and discussed several times at a public workshop held at the National 
Academy of Sciences on October 11-12, 2004 in Washington D.C. See generall_v 
NAT'L ACAD. OF Sc1s., Guidelines for Human Embryonic Stem Cell Research: A 
Public Workshop, at http://dels.nas.edu/bls/stemcell.html (last visited Feb. 15, 2005) 
[hereinafter NAT'L AcAD. OF Sers., Public Workshop]. 
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the federal government invests in biomedical research each year.14 This 
policy also contributes to the decision reached by the many thousands of 
people who have received AR services and who do not want biological 
offspring beyond their own families to simply make no decision or an 
affinnative decision to allow the cryopreservation of their leftover embryos 
to linger on-perhaps at the discretion of an AR clinic.15 Consequently, the 
numbers of embryos derogated to cryopreservation with no chance of 
implantation for reproduction should rise in the United States in 
conjunction with advancement and use of AR services.16 
President Bush has stated repeatedly that his policy on human 
embryonic stem cell research is rooted deeply in respect for embryos and 
human life, 17 and the same is said by Leon Kass who chairs the President's 
Council on Bioethics and is reflected in the Council's position.18 It seems 
terribly inconsistent to me to be creating embryos without foresight about 
their fate, without any meaningful and direct government oversight, and 
placing them in cryopreservation purgatory for extended periods of time 
14. The National Institutes of Health (NIH) alone was a conduit for a federal budget of 
$28 billion in 2004, and NIH's budget for 2005 is $28.6 billion. Jonathan Weisman, 
2006 Cuts in Domestic Spending on Table, WASH. POST, May 27, 2004, at Al; Drug 
Development: Medicine Price Hike Highlights Controversy of Government Funding 
Drug Research, MED. LETTER ON CDC & FDA, June 20, 2004, available at 2004 WL 
55170701. 
15. See supra note 10 and accompanying text (comments of Dr. Kadereit). Resistance to 
putting one's embryos up for donation in this context is not surprising, for many seek 
AR services rather than adoption because of the value they place on biological ties to 
offspring. For case studies that illustrate this point, see 18 Ways to Make a Baby (PBS 
television broadcast, Oct. 9, 2001). See also Miller, No. 02-L-7394. 
16. Expanding use of AR services in the United States is driven by many influences, 
including demographic and cultural trends resulting in delays in reproduction and 
acceptance of AR, the number of AR service providers and their marketing efforts, 
the profitability of providing AR services, and increasing scientific capabilities, 
including preimplantation genetic diagnosis (PGD) that allows genetic selection 
among available embryos before implantation. See generally Malinowski, supra note 
3; John A. Robertson, Extending Preimplantation Genetic Diagnosis: The Ethical 
Debate, 18 HUM. REPROD. 465 (2003). 
17. Heather L. Fowler, Misapplied Ethical Considerations: U.S. Federal Stem Cell 
Mandates lack Global Focus and Market Foresight, 36 CORNELL INT'L L.J. 521, 534 
(2004); Tommy G. Thompson, Why Bush's Stem Cell Policy is Reasoned-and Why 
it's Working, USA TODAY, Aug. 16, 2004, at llA, available at 
http://www.usatoday.com/news/opinion/editorials/2004-08-15-stem-cells _ x.htm. See 
generally supra note 13. 
18. See LEON R. KASS, LIFE, LIBERTY AND THE DEFENSE OF DIGNITY: THE CHALLENGE FOR 
BIOETHICS 130 (Encounter Books 2002). For the Council's position on this issue and 
others, see http://www.bioethics.gov. See also PRESIDENT'S COUNCIL, REPRODUCTION 
AND RESPONSIBILITY, supra note 3. 
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without any intention of using them when there are potential medical 
benefits to existing living, breathing people. The Bush Administration and 
supporters of his policy question this potential and suggest alternatives to 
hESCR.19 Doing so necessitates speculation in the negative about the 
outcome of ongoing and future scientific research with hESCs, which is a 
mirror reflection of the Administration's major criticism of advocates for 
hESCR-that they are speculating (in the positive) when they identify 
potential clinical applications.20 The fact is that the vast majority of Nobel 
Laureates in science recognize human health potential in hESCR and 
support U.S. federal funding of it.21 Presumably, the visionaries excited 
about hESCR are hyping the potential clinical use, but the funny thing 
about science is that you never really know unless you try. I have seen 
accomplishments in science during the last decade, including completion of 
a map of the human genome ahead of schedule and under budget, that I was 
told by many top medical and science people in the early 1990s would not 
happen.22 The division between the pragmatists in medicine and visionaries 
in science23 now has shifted beyond mapping the human genome to making 
medical sense out of it, and we are all debating how quickly that will come. 
II. ONGOING BIOMEDICAL RESEARCH AND DEVELOPMENT (R&D) 
My position on hESCR now established, let us sketch a regulatory 
picture for the future development of stem cells in application-and do that 
with some cautious skepticism about how quickly these applications are 
going to come. When I contemplate applications, I do not view the future 
19. Research with adult stem cells is frequently pointed to as an alternative that is 
showing more scientific advancement. For example, President Bush has and continues 
to make this argument. See, e.g., Address to the Nation on Stem Cell Research, supra 
note 13. See generally infra note 21. 
20. Associated Press, First Lady Joins Stem Cell Debate (Aug. 9, 2004), available at 
http://www.cbsnews.com/stories/2004/07/28/politics/printable632432.shtml. 
21. Letter from Nobel Laureates to President Bush (Feb. 21, 2001), available at 
http://www. washingtonpost. com/ ac2/wp-dyn/ A3 7117-200 1 F eb21? language=prin ter. 
See generally COMMITTEE ON THE BIOLOGICAL AND BIOMEDICAL APPLICATIONS OF 
STEM CELL RESEARCH, STEM CELLS AND THE FUTURE OF REGENERATIVE MEDICINE 
(Nat'l Acad. Press 2002) (discussing stem cell research and its potential to improve 
human health); ANN B. PARSON, THE PROTEUS EFFECT: STEM CELLS AND THEIR 
PROMISE FOR MEDICINE (Joseph Henry Press 2004). See also Harvey Fineberg, 
Remarks at the National Academy of Sciences Public Workshop (Oct. 12, 2004) 
(transcript on file with author); NAT'L ACAD. OF Sers., Public Workshop, supra note 
13. 
22. Michael J. Malinowski, Separating Predictive Genetic Testing from Snake Oil: 
Regulation, Liabilities, and Lost Opportunities, 41 JURIMETRICS J. 23, 26 (2000). 
23. Id. at 24 n.3, 25 n.4 and accompanying text. 
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from only a clinical delivery standpoint. Rather, my perspective, shaped by 
years of law practice and other commercial sector experience, is very much 
from the laboratory bench to market. Many important commercial 
applications are research tools to enable other basic research in human 
health and corollary applications.24 
The timing of jolting, fundamental advancements in hESCR during 
the late 1990s has been politically problematic for the field. The isolation 
of human stem cells regorted in 1998 by Geron Corporation and the 
University of Wisconsin 5 came almost literally on the tail of Dolly-the 
first successfully cloned mammal. 26 Dolly triggered an immediate reaction 
of fear of cloning for human reproduction, and human cloning and 
reproduction have been extensively commingled in the popular press, 
public mindset, and legislative activity ever since. 27 This cloning override 
between therapy and reproduction is not entirely unfair because, in fact, the 
science does carry over. If one develops techniques such as somatic cell 
nuclear transfer28 to engage in hESCR for patient-tailored medicinal 
applications, presumably those could be used in AR. In fact, the technique 
was developed in the process of cloning mammals for reproduction­
Dolly. The human reproduction concern "has legs" from a pragmatic point 
of view because the U.S. federal government does not regulate AR in a 
comprehensive, direct manner.29 At the very least, drawing this connection 
24. Consider the myriad compounds that have been patented and, through licenses and 
commercial royalty arrangements, used in diverse clinical applications. See generally 
BOSTON CONSULTING GROUP, THE PHARMACEUTICAL INDUSTRY INTO ITS SECOND 
CENTIJRY: FROM SERENDIPITY TO STRATEGY 38-39 (Jan. 1999). 
25. Terry Devitt, Wisconsin Scientists Culture Elusive Embryonic Stem Cells (Nov. 5, 
1998), at http://www.news.wisc.edu/3327html. 
26. For more information, visit the web site of the Roslin Institute in Edinburgh, 
Scotland, where Dolly was created, at http://www.roslin.ac.uk/public/cloning.html. 
See also Dolly the Sheep, in WIKIPEDIA ENCYCLOPEDIA, at http://en.wikipedia.org/ 
wiki/Dolly _the _sheep (last modified Feb. 2, 2005). 
27. See Paul Lesko & Kevin Buckley, Attack of the Clones ... and the Issues of Clones, 3 
COLUM. Ser. & TECH. L. REV. 1 (2002), at http://www.stlr.org/cite.cgi? 
volume=3&article=3; Meredith Lewis, Book Note, Age of Human Cloning and the 
Constitutional Crisis that May Result, 6 J.L. & FAM. STUD. 171 (2004); Shawn E. 
Peterson, Note, A Comprehensive National Policy to Stop Human Cloning: An 
Analysis of the Human Cloning Prohibition Act of 2001 with Recommendations for 
Federal and State Legislatures, 17 NOTRE DAME J.L. ETHJCS & PUB. POL'Y 217, 217-
18 (2003). 
28. STEM CELL NETWORK, What is Somatic Cell Nuclear Transfer {SCNT)?, at 
http://www.stemcellnetwork.ca/guide/focus.php?=id=l 74 (last visited Feb. 10, 2005); 
see COMMITTEE ON THE BIOLOGICAL AND BIOMEDICAL APPLICATIONS OF STEM CELL 
RESEARCH, supra note 21, at 10-12. 
29. See supra notes 4-7 and accompanying text; see also infra notes 73-76 and 
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is not unreasonable, illogical, irrational or unfair. Similarly, baseline moral 
and religious objections to destroying embryos stirs the issues of cloning 
for therapy and cloning for reproduction into each other. 
Even with the reelection of President Bush and absent a change in 
federal policy on hESCR, it is certain that hESCR is going to continue. The 
research will move forward primarily as a private market endeavor. In fact, 
NIH is encouraging this by grant funding efforts to make cell lines 
available for private research and development. 30 On a personal note, as a 
taxpayer and as one who has spent the vast majority of his career practicing 
law and engaging in scholarship in the area of technology transfer and 
development in biotechnology, I find the Administration's position to be 
hypocritical and generally troubling. It is no consolation to me to hear that 
the Administration's position on hESCR is tempered by the fact that NIH, 
in addition to putting up $25 million for direct support of this research, is 
also putting up $25 million to deal with the transaction cost of complying 
with its own restrictive policy on federal funding.31 Rather, it seems 
awfully hypocritical to me to put so much government money allegedly 
committed to research into lowering transaction costs created because the 
Bush Administration does not want to support that research in an open 
way-though implicitly the Administration acknowledges the importance 
of hESCR enough to grant fund efforts to "Coase around"32 its own policy. 
Even without NIH funding to bridge transaction costs created by 
President Bush's policy, the biomedical establishment that is dependent 
upon federal funding is committed to doing this research, and is going to 
find a way to do some of it-there is no question. We are seeing that 
happen now. Notably, there are few instances where major universities­
Harvard33 and Stanford34-have shadowed the arrangement between Geron 
30. 
31. 
32. 
33. 
34. 
accompanying text. See generally Malinowski, supra note 3. 
0. Carter Snead, Keynote Address: Preparing the Groundwork for a Responsible 
Debate on Stem Cell Research and Human Cloning, 39 NEW ENG. L. REV. 479 
(2005). 
See id A similar message was issued by a James Battey, Director, National Institute 
on Deafuess and Other Communication Disorders, on October 12, 2004 at Guidelines 
for Human Embryonic Stem Cell Research, a workshop organized and hosted by the 
National Academy of Sciences, October 12-13, 2004, Washington, D.C., in which the 
author participated. 
See generally Ronald Coase, The Problem of Social Cost, 3 J.L. & ECON. I (1960). 
Harvard's effort is the Harvard Stem Cell Institute, which announced in March 2004 
that it had developed seventeen new embryonic stem cell lines. See Harvard Stem 
Cell Institute, HARV. GAZETTE, Apr. 22, 2004, available at http://www.news. 
harvard.edu/gazette/2004/04.22/science.html. 
�tanford. has established the Institute for Cancer/Stem Cell Biology and Medicine, mformatlon about which is available at http://med.stanford.edu/institutes/. 
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and the University of Wisconsin that produced the 1998 fundamental 
hESCR advances.35 These universities have put up administrative divisions 
and created separate entities to engage in hESCR without federal funding.36 
The problem is that there are not too many schools in the position of 
Harvard and Stanford. I teach at Louisiana State University, a good school 
with some A-level science through the Pennington Biomedical Research 
Center, AgCenter, School of Veterinary Medicine, Health Sciences Center, 
and so forth, but LSU is not positioned financially or politically to create a 
quasi-private entity for hESCR. Even with state support, doing so would be 
extremely difficult, though LSU does receive a significant amount of 
federal funding to support research projects throughout the LSU System. 
LSU is representative of a considerable portion of the research university 
community, and mechanisms created by a few of the most renowned 
private institutions, even if successful and duplicated, are unlikely to offset 
the loss of meaningful access to tens of billions of dollars in federal 
funding annually for an entire field of science. 
In conjunction with private universities, a few states are getting 
directly involved in hESCR. Most notably, California has committed $3 
billion over ten years.37 Without putting u� the same billions of dollars, 
New Jersey too has taken a positive stand. 8 Nevertheless, other states as 
diverse as Massachusetts and Louisiana have either seen supportive 
legislative initiatives fail or actually considered legislative proposals to 
move in the opposite direction.39 Moreover, California's financial support 
35. For information about this arrangement, visit the site of the Wisconsin Alumni 
Research Foundation, at http://www.warf.ws, which holds composition of matter 
patents in stem cell lines-a potential basis for property claims to all stem cell lines. 
36. See supra notes 31-32 and accompanying text. 
37. John M. Broder & Andrew Pollack, Californians to Vote on Spending $3 Billion on 
Stem Cell Research, N.Y. TIMES, Sept. 20, 2004, at A l; Dan Vergano, Embryonic 
Imbroglio, USA TODAY, Oct. 27, 2004, at D6. 
38. Wesley Chang, Comment, Arrested Development: Patent Laws, Embryonic Stem Cell 
Research, and the Organ Black Market, IO Sw. J.L. & TRADE AM. 407, 424-25 
(2004). 
39. Louisiana already recognizes the embryo as a juridical person. LA. REV. STAT. ANN. 
§§ 121-33 (West 2004). A legislative proposal to ban human cloning that would have 
effectively prohibited hESCR research in the state regardless of the source of funding 
was circulated in 2004. See H.R. 803, 2004 Sess. (La. 2004). Massachusetts, though 
in a heated biotech race with California, was unable to enact proposed legislation 
supporting stem cell research. However, Thomas M. Finneran, the former Speaker of 
the House, who opposed that legislation, is now supportive in his role as Chief 
Executive Officer of the Massachusetts Biotechnology Council. See Mark 
Zimmerman, An Odd Job for Tom Finneran, BOSTON GLOBE, Oct. 3, 2004, at DJ 0 
(letter to the editor); Scott S. Greenberger & Frank Phillips, Stem Cell Bill Tops 
Agenda as Legislature Convenes, BOSTON GLOBE, Jan. 6, 2005, at Al; John 
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cannot offset the tens of billions of dollars NIH invests annually in 
biomedical research and the associated, potentially enormous opportunity 
cost.40 As we witnessed through the Human Genome Project, meaningful 
support from the U.S. government in areas of research can have a 
distinctive effect in terms of establishing prioritization, "critical mass" 
participation, and focus throughout the global science community. 
III. FUTURE HUMAN HEALTH APPLICATIONS 
So what is the opportunity cost in terms of human health 
applications? Throughout this symposium,41 the NAS's forum last month,42 
and the scientific and popular literature,43 many potential human health 
applications of ongoing hESCR have been identified. Some of the more 
dramatic applications are a cure for diabetes, effective treatment for 
Alzheimer's, and spinal cord repair.44 President Bush's policy of restricted 
funding for hESCR is premised on the assumption that the applications of 
the technology are years in the future. However, there are immediate and 
certain applications of hESCR that refute this assertion. Deeper knowledge 
about cell differentiation could have a profound impact on basic biomedical 
research. Consider creation of cell lines free of non-human animal cultures, 
an abundance of cell lines tailored to genetic characteristics of specific 
disease populations, novel vectors, and other biomaterials which, through 
material transfer and development agreements, become valuable tools used 
in many areas of biomedical research. If human experience in biomedical 
R&D is any indication, incremental clinical applications in the process of 
moving from the present towards effective therapies are actually probable 
with meaningful investment in hESCR. For example, consider use of cell 
manipulation techniques to conduct much more precise toxicity testing­
perhaps to better isolate adverse events associated with pharmaceuticals 
Strahinich, Finneran Now Backs Stem Cell, BOSTON HERALD, Nov. 10, 2004, at 42. 
40. See supra note 14 and accompanying text (noting that the NIH has a budget of $28.6 
billion in 2005). 
41. See generally Symposium, Stem Cell Research to Human Cloning: W'here Do We 
Draw the Line?, 39 NEW ENG. L. R.Ev. 477, 477-714 (2005). 
42. See NAT'L ACAD. OF Sc1s. Public Workshop, supra note 13. 
43. See, e.g., COMMITTEE ON THE BIOLOGICAL AND BIOMEDICAL APPLICATIONS OF STEM 
CELL RESEARCH, supra note 21; p ARSON, supra note 21. 
44. Research endeavors for human health applications include muscular dystrophy, 
autoimmune disorders (lupus, multiple sclerosis, and deafness), cells for drug testing, 
replacement salivary gland cells for patients treated with radiation for cancers of the 
head and neck, teeth regeneration, infertility, baldness, depression, neurogenesis, 
fortification of heart muscle, immune system tolerance for organ transplant patients, 
bone r�generation, breast reconstruction, Parkinson's disease, making organs and 
other b10-structures, spinal cord injury, and aging. PARSON, supra note 21, at 2 l 9-32. 
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already on the market and commonly used: 
Take the example of a Geron team's having turned human ES 
[embryonic stem] cells into what it believes are hepatocytes, the 
liver's primary specialized cell. If hepatocytes could be mass 
produced from ES cells, drugmakers, who must show that a new 
drug has no adverse effects on the liver, would have vast 
quantities of liver cells. Currently, a chief source of liver cells for 
45 drug tests are cadavers. 
As this example suggests, cellular differentiation techniques might 
help to modify or at least make better choices among a range of existing 
treatments in areas such as oncology. The capability to readily and cost­
effectively grow particular kinds of cells may even enable some patient­
tailored toxicity testing. 
The hESC lines in existence on August 9, 2001-those which may be 
used in federally funded research under the Bush Administration's 
policy46-were created with exposure to mouse cultures, are limited in their 
genetic diversity, generally are of questionable vitality and quality, and in 
many instances are encased with proprietary interests. 47 Use of mouse 
feeder cells in the creation of these lines, reflective of the state of science at 
that time, introduces a muddle of xenotransplantation complications if 
these lines are to be the basis for human health applications.48 In January 
2005, a study was issued by researchers at the University of California San 
Diego and the Salk Institute for Biological Studies in La Jolla, indicating 
that the lines probably are too innately contaminated to ever serve as the 
basis for human health applications.49 
Assuming we see meaningful human health applications from hESCR 
over the next several years in spite of limitations on federal financial 
support, are existing regulations and regulatory regimes for human health 
products sufficient to handle them? I do believe that the FDA, in 
collaboration with sister agencies as necessary under the Coordinated 
45. Id. at 223. 
46. See supra note 1 3  and accompanying text. 
47. See Malinowski, supra note 3, at 184 n.30 1 .  
48 . R. Alta Charo, Existing Federal, State and Voluntary Regulation of Embryonic Stem 
Cell Research (Oct. 2004 ), available at http://dels.nas.edu/bls/stemcells/charo.pdf 
(distributed at the NAT'L ACAD. OF Sc1s., Public Workshop, supra note 1 3). For more 
information about xenotransplantation and related science and regulatory issues, see 
CENT. FOR BIOLOGICS EVALUATION & RESEARCH, U.S. FOOD & DRUG ADMIN., 
Xenotransplantation Action Plan, at http://www.fda.gov/cber/xap/xap.htm (last 
modified June 29, 2004). 
49. See Kaplan, supra note 13. 
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Framework,50 can rise to the occasion of sufficiently regulating products 
developed through hESCR. I say that fully aware tha! we h�ve a ve�y 
troubling time in front of us regarding the FDA. I was dtrectly mvolved m 
the modernization of the FDA through scholarship and industry 
representation.51 A lot of good was done to increase the crossover of new 
science into commercial applications. User fees have greatly expanded the 
FDA's resources, and also created much more dialogue among the FDA, 
industry, and academia.52 Ultimately, you end up in a world where a very 
thick and long-standing wall was taken down between industry and the 
government through regulatory reform. While razing this wall arguably 
was necessary to fuel the genomics revolution,53 accountability 
mechanisms must be added in its place to ensure some regulatory 
checkpoints.54 The ongoing Cox-2 controversy, coupled with incidents such 
50. Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,302 (June 
26, 1986). Under this policy, federal regulatory entities are supposed to collaborate to 
regulate biotechnology products and not subject those products to added regulation 
just because biotechnology processes are used to make them. See Michael J. 
Malinowski, FDA Regulation of Biotechnology Products for Human Use, in 
ENCYCLOPEDIA OF ETHICAL, LEGAL AND POLICY ISSUES IN BIOTECHNOLOGY 215 
(Thomas H. Murray & Maxwell J .  Mehlman eds., 1999) . 
51. This modernization refers to implementation of the Food and Drug Administration 
Modernization Act of 1997. Pub. L. No. 105-115, 111 Stat 2296 (codified throughout 
21 U.S.C.) [hereinafter FDAMA]. 
52. Prescription Drug User Fee Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491 
(codified throughout 21 U.S.C.) [hereinafter PDUFA I]. PDUFA I was reauthorized 
(PDUFA II) in the context ofFDAMA. Prescription Drug User Fee Act of 1994, Pub . 
L. No. 102-571, 106 Stat. 4491 (codified in scattered sections of 21 U.S.C), renewed 
as an addendum to the FDAMA. The FDAMA-renewed the user fee program for five 
years and introduced new performance goals and other fundamental adjustments. See 
Malinowski, supra note 50; Prescription Drug User Fee Ammendments of 2002, Pub. 
L. No. 107-188, 116 Stat. 687 (codified throughout 21 U.S.C.) [hereinafter PDUF A 
III] (extending the program to Sept. 30, 2007). See generally Fooo & DRUG ADMIN .. 
PUDFA III Five-Year Plan, available at http://www.fda.gov/cc/pdufa3/ 
2003plan/default.html (July 2003). 
53. For support of federal technology transfer policy and practice, see generally NAT'L 
INSTS. OF HEALTH, NIH Response to the Conference Report Request for a Plan to 
Ensure Taxpayers' Interests are Protected, available at http://www.nih.gov/ 
news/070101wyden.htm (July 2001); GEN. ACCOUNTING OFFICE, REPORT TO 
CONGRESSIONAL COMMITrEES: TECHNOLOGY TRANSFER, ADMINISTRATION OF THE 
BAYH-DOLE ACT BY RESEARCH UNIVERSITIES, GAO/RCED-98-126 (May 1998), 
available at http://www.gao.gov/archive/l 998/rc98 l 26. pdf [hereinafter GA 0 
REPORT]. 
54. See generally Timothy Caulfield, Globalization, Conflicts of Interests and Clinical 
Research: An Overview of Trends and Issues, 8 WIDENER L .  SYMP. J. 31 (2001); Janet 
Fleetwood, Conflicts of Interest in Clinical Research: Advocating for Patient 
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as the alleged failure of Lilly to disclose troubling clinical data for Prozac 
which has been on the market for years, may end up being the "thalidomide 
of 2005" that triggers some major reform.55 
With that being said, the FDA has been extremely resourceful and 
dynamic responding to many scientific and other challenges during the last 
decade, and they have made some administrative changes that position 
them well to handle hESCR product applications. Most notably, they have 
been developing a "tissue products track" and have centered review for all 
drugs, including biologics, in the Center for Drug Evaluation and Research 
(CDER).56 At least in theory, by centralizing pharmaceuticals in CDER, the 
Agency opened up the Center for Biologics (CBER)57 to focus on areas like 
hESCR. Unfortunately, as I learned through a conversation at the NAS 
workshop,58 the Agency also has gutted a great deal of CBER's resources 
and human talent, and that simply has to be corrected. 
Now, stepping beyond regulatory oversight, the privatized, extreme 
commerce approach59 President Bush is taking with hESCR will have a 
significant impact on how and the extent to which hESCR is applied-both 
in biomedical research and in human health markets. Immediate experience 
Subjects, 8 WIDENER L. SYMP. J. 105 (2001); Patricia Kuszler, Curing Conflicts of 
Interest in Clinical Research: Impossible Dreams and Harsh Realities, 8 WIDENER L. 
SYMP. J. 115 (2001); Michael J. Malinowski, Academic-Industry Collaborations in 
the Clinic, 8 WIDENER L. SYMP. J. ii (2001); Michael J. Malinowski, Institutional 
Conflicts and Responsibilities in Anage of Academic-Industry Alliances, 8 WIDENER 
L. SYMP. J. 47 (2001); Pilar N. Ossorio, Pills, Bills and Shills: Physician-Researcher's 
Conflicts of Interest, 8 WIDENER L. SYMP. J. 75 (2001); Cynthia Robbins-Roth, From 
Alchemy to /PO: The Businesses of Biotechnology, 8 WIDENER L. SYMP. J. 153 
(2001); Erica Rose, Financial Conflicts of Interest: How Are We Managing?, 8 
WIDENERL. SYMP. J. l (2001). 
55. Ken Belson, Lilly Shares Fall on Report About Prozac Documents, N.Y. TIMES, Jan. 
1, 2005, at C2; Alex Bernson, An Industry in Poor Health, N.Y. TIMES, Dec. 18, 2004, 
at Al; Barnaby J. Feder, The Fallout from Celebrex, N.Y. TIMES, Dec. 18, 2004, at 
Bl; Gina Kolata, A Widely Used Arthritis Drug is Withdrawn, N.Y. TIMES, Oct. 1, 
2004, at Al; Barry Meier, A Top Republican to Offer Drug Data Bill, N.Y. TIMES, 
Dec. 10, 2004, at C3; Anahad O'Connor & Denise Grady, Problems May Send Many 
Patients Back to Good Old Aspirin, N.Y. TIMES, Dec. 18, 2004, at Bl. Several major 
pharmaceuticals, in an effort to preempt government mandates, are now posting much 
more clinical data voluntarily. Meier, supra. 
56. See CENT . FOR DRUG EVALUATION & RESEARCH, U.S. FOOD & DRUG ADMIN., at 
http://www.fda.gov/cder (last updated Feb. 18, 2005). See generally Charo, supra 
note 48. 
57. See CENT. FOR BIOLOGICS EVALUATION & RESEARCH, U.S. FOOD & DRUG AoMIN., at 
http://www.fda.gov/cber (last updated Feb. 1, 2005). 
58. NAT' L ACAD. OF Scis., Public Workshop, supra note 13. 
59. See generally Sean M. O'Connor, Intellectual Property Rights and Stem Cell 
Research: Who Owns the Medical Breakthroughs?, 39 NEW ENG. L. REv. 665 (2005). 
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with hESCR is telling. When President Bush issued his pol icy on hESCR 
on August 9, 200 1 ,  my immediate reaction was, "Does he assume these �e l l  
lines are free o f  intellectual property entanglements-that they are subject 
to free use?" I knew Geron had licenses from the University of W isconsin 
and had exercised rights over a lot of the better lines. 60 Sure enough, Geren 
was pulled into negotiations with NIH representatives soon after, and the 
result was that the lines are accessible via licenses, but on terms that many 
researchers find unfavorable.61 
What are the costs of a wholly privatized approach in the field of 
hESCR? Well, one of the costs is that extensive proprietary interests, an 
extension of the source of funding, results in a loss of derivation cel l  l ines 
that would potentially make a significant impact in the field. Again, g iven 
the proprietary nature of the research and related information, you also end 
up with a loss of public awareness and accountability. Compan ies need 
only disclose to the extent necessary to obtain patents, and they usually go 
to great extremes to shroud invention with confidentiality and disclosure 
agreements and other secrecy measures to maintain patentabi lity and 
competitive advantages, and to avoid public relations problems.62 In fact, 
the U.S .  government is sacrificing a major entitlement to information in 
hESCR under standard federal technology transfer law and policy. Even a 
small amount of federal funding entitles the U.S.  federal government to 
receive reports about resulting inventions.63 The government also receives a 
non-exclusive right to use inventions that come out of your taxpayer dol lars 
in its own internal research,64 and the U.S.  government engages in 
60. 
61.  
62. 
63. 
64. 
For more information about these licenses, visit the sites of Geron Corporation, at 
http://www.geron.com/, and the Wisconsin Alumni Research Foundation, at 
www.warf.ws. 
See O'Connor, supra note 59. 
This is the author' s observation based upon years of experience and practice in the 
field. See also Rebecca S. Eisenberg, Proprietary Rights and the Norms of Science in 
Biotechnology Research, 97 YALE L.J. 1 77 ( 1987). 
See Patent Rights in Inventions Made with Federal Assistance, Pub. L. No. 96-5 1 7, 94 
Stat. 3019 (1980) (codified at 35 U.S.C. §§ 200-2 1 2) (the Bayh-Dole Act); 
Technology Innovation Act, Pub. L. No. 96-480, 94 Stat. 23 1 1  ( 1 980) (codified at 1 5  
U.S.C. §§ 370 1 -37 1 7) (the Stevension-Wydler Technology Innovation Act); Federal 
Technology Transfer Act of 1 986, Pub. L. No. 99-502, 1 00 Stat. 1 785 ( 1 986) 
(codified at 15 U.S.C. §§ 3 7 1 0a-d); Exec. Order No. 1 2 5 9 1 ,  52 Fed. Reg. 1 3 ,4 14 
(Apr. 1 0, 1987); American Technology Preeminence Act of 1 99 1 ,  Pub. L .  No. 1 02-
245, 1 06 Stat. 7 ( 1 992) (codified in scattered sections of 15 U.S.C.); National 
Technology Transfer and Advancement Act of 1 995, Pub. L. 1 04- 1 13,  1 1 0 Stat. 775 
( 1 996) (codified in scattered sections of 1.5 U.S.C.). 
See the federal technology transfer policy, which consists of the authority cited supra 
note 63. 
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significant research in its NIH,65 FDA,66 and other laboratories. Keeping 
federal taxpayer dollars removed from hESCR means that we as taxpayers 
will not have standard entitlement to access inventions in the field of 
hESCR unless that access is acquired through government contracts or 
other measures. 67 
As a point of comparison, consider the United Kingdom's policy on 
hESCR. The United Kingdom government has implemented a mandatory 
licensing approach for all hESCR in conjunction with endorsing hESCR 
and making government financial support accessible.68 Consequently, 
relative to the United States, the U.K. government knows much more about 
what hESCR is taking place on its soil even if much of that information 
remains proprietary. Moreover, with government support and a favorable 
regulatory environment, the United Kingdom has become an attractive 
professional destination for those engaged in hESCR, and perhaps investors 
also. This leads to yet additional possible U.S. cost consequences of the 
Bush policy----consequences that bring us back to basic research. First, 
science is global, and, if one believes in market forces, then talent and 
money in the field of hESCR are likely to shift to where there is the 
greatest opportunity. Second, continued investment of many billions of 
dollars in basic research on an annual basis is a reflection of public and 
political support of biomedical research. Many human health applications 
are particularly attributable to that investment including, at least 
historically, significant support for curiosity-driven research. Few private 
investors are attracted to curiosity-driven research, so we can assume that 
much of that has been driven out of hESCR under the Bush policy. 
CONCLUDING THOUGHTS 
I would like to close by making a "big picture" conclusion about U.S. 
policy and sentiment regarding hESCR. To do so, I ask you to step back to 
the announcement in 1998 by Geron Corporation and the University of 
Wisconsin that they had successfully isolated human embryonic stem 
cells.69 This was a threshold event for the field which, subsequently, has 
65. For information about the NIH' s  laboratories, see http://www.nih.gov. 
66. For information about the FDA's laboratories, see http://www.fda.gov. 
67. The author's understanding, based upon experience practicing in the field, is that the 
United States has not exercised these licenses in a meaningful manner thus far. 
68. Anne McLaren, University of Cambridge, Address at Guidelines for Human 
Embryonic Stem Cell Research: A Public Workshop (Oct. 12, 2004) (explaining the 
United Kingdom' s  approach to hESCR). This address was part of a workshop hosted 
by the National Academy of Sciences. See NAT'L ACAD. OF Sc1s., Public Workshop, 
supra note 1 3 .  
69. Press Release, Geron Corp., First Derivation of Human Embryonic Stem Cells (Nov. 
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been advancing in exciting and often unpredictable ways. 70 There certa inly 
is a before and an after in terms of scientific and pubic debate over hESC R. 
Again, this timing was unfortunate from an hESCR policy 
perspective, for it came while the world was absorbing news of Dolly the 
sheep and contemplating cloning for human reproduction as a possible 
reality.71 Therapeutic and reproductive cloning have been commingled in 
legislative and public debate since, and that debate has been extens ive-in 
the media and in federal and state legislatures. 72 
In fact, as mentioned earlier,73 the present state of regulation of AR in 
the U.S. makes it impossible to provide assurances to quell ongoing 
concern that advances in hESCR will spill over into human reproduct ion . 7.i 
When I teach Bioethics: Law and Policy as I did again thi s  semester, as an 
assignment, I send my students onto the Internet with the instrnction to 
pretend that they are seeking AR services and to bring back a summary of 
what they find. It is amazing to shock the "MTV generation," and yet it 
happens every time. What they find is aggressive commercialism in the 
most fundamental area of medicine from a humanity and society 
perspective. Although the United States does have a model compliance 
program for AR clinics written up by the Centers for Disease Control and 
Prevention (CDC) over a decade ago, no states have adopted it. The United 
States depends on a contract between CDC and SAR T-the professional 
society that oversees assisted reproduction-and the voluntary information 
that they generate,75 as recognized by the President's Council on 
Bioethics.76 Although I am fairly comfortable with reporting by highly 
responsible institutions such as the Harvard-aff iliated Brigham and 
70. 
71 .  
72. 
73. 
74. 
75. 
76. 
5, 1 998), available at http://www.geron.com/pressview.asp?id=56 l&print=yes; see 
also John Miller, Comment, A Call to Legal Arms: Bringing Embryonic Stem Cell 
Therapies to Market, 1 3  ALB. L.J .  SCI. & TECH. 555 (2003). 
See NAT'L ACAD. OF SCIS., Public Workshop, supra note 1 3 .  
See supra notes 22-24. 
See generally Richard Guerra, Comment, Therapeutic Cloning As Proper Subject 
Matter for Patent Eligibility, 43 IDEA 695 (2003); Duane Nash, Recommended 
Response for Human Cloning Patent Applications, 42 IDEA 279 (2002); Peterson, 
supra note 26; Suzanne H. Rhodes, Comment, The D ifficulty of Regulating 
Reproductive and Therapeutic Cloning: Can the United States Learn Anything from 
the Laws of Other Countries?, 2 1  PENN. ST. INT'L L. REV. 341  (2003); David M. 
Smolin, Should a Ban on Reproductive Cloning Include a Ban on Cloning for 
Purposes of Research or Therapy?, 32 CUMB. L. REV. 487 (2002). 
See supra notes 5-8 and accompanying text. 
See generally Malinowski, supra note 3. 
See supra note 7 and accompanying text. 
See PRESIDENT'S COUNCIL, REPRODUCTION AND RESPONSIBILITY surpra note 3 at 54-
63. 
' 
' 
2005] APPLYING THE CURRENT POLICY IN THE FUTURE 663 
Women's Hospital and Boston's Children's Hospital, these institutions are 
not necessarily representative of the hundreds of for-profit clinics across 
the country providing the majority of AR services. 
So, at the end of the day, I believe that U.S. policy on hESCR is as 
entangled with Dolly and fears about human cloning in reproduction as 
therapeutic and reproductive cloning have been coupled in legislative and 
public debate.77 I support hESCR passionately, while also recognizing that 
it is asking a lot of the public simply to trust without having some kind of 
assurance that the science will not be carried over into human reproduction 
and misused. Accordingly, in my opinion, debate over hESCR and U.S. 
law-policy should be shifted in the direction of providing that assurance. 
77. See supra note 72 and accompanying text. 
